Peptide A · Tissue and thymic peptides
BPC-157
Synthetic pentadecapeptide research material
Body Protection Compound 157BPC 157
Open the 10 mg price board ↗Check BPC-157 human evidence ↗Research price & evidence comparisonBPC-157
BPC-157
vs TB-500.
BPC-157 and TB-500 frequently appear together in research-catalog searches, but they are distinct seller-labelled materials with separate identities, price boards, document trails, and FDA safety-context records. This page compares the current public US research-market footprint without treating either listing category as a medical option.
7shared seller pages
Same10 mg / 10 mg board sizes
10rows with public evidence routes
0clinical or effect rankings
Identity before price
Two records, kept separate.
BPC-157 is catalogued here as a synthetic pentadecapeptide research material; TB-500 is catalogued as thymosin beta-4 research material. A shared 10 mg board size makes list-price normalization possible within each board, but it does not make the compounds chemically, biologically, or clinically interchangeable.
Peptide B · Tissue and thymic peptides
TB-500
Thymosin beta-4 research material
Thymosin beta-4 fragmentTB500
Open the 10 mg price board ↗Check TB-500 identity and human evidence ↗Like-for-like fields
Commercial footprint, side by side.
Price ranges use rows marked in stock. “Public evidence route” means a seller exposed a document link; it does not establish authenticity, chain of custody, purity, sterility, or vial contents.
| Comparison field | BPC-157 | TB-500 |
|---|---|---|
| Editorial family | Tissue and thymic peptides | Tissue and thymic peptides |
| Seller-listed identity | Synthetic pentadecapeptide research material | Thymosin beta-4 research material |
| Nominal board size | 10 mg | 10 mg |
| Available list range | $40.00–$92.00 | $49.00–$124.00 |
| Median available price | $52.79 | $62.69 |
| Lowest available / mg | $4.00 | $4.90 |
| Available rows | 5 of 7 | 5 of 7 |
| Public evidence routes | 5 rows | 5 rows |
| Evidence only on request | 1 rows | 1 rows |
| Available-price spread | 130% | 153% |
| Snapshot checked | Jul 23, 2026 | Jul 23, 2026 |
Unit warning
Per-milligram figures normalize the seller’s nominal quantity only. They are not a cross-compound value, potency, effect, or dose comparison.
Seller overlap
Where the current boards intersect.
Both sit in Peptide Local’s tissue and thymic research family and share much of the same seller set, so readers often need to separate a genuine price-footprint comparison from an unsupported equivalence claim.
- AminoCore Research
- Biotech Peptides
- Core Peptides
- Pepta Labs
- Prime Peptides
- Pure Health Peptides
- Purgo Labs
No left-only seller in the qualified rows.
No right-only seller in the qualified rows.
Three reading rules
What keeps this comparison honest.
- 01
Compare each compound’s sellers against its own exact-size board before looking across compounds.
- 02
A lower dollar-per-milligram figure does not establish equal research value, potency, purity, or suitability.
- 03
FDA’s cited compounding-risk context applies as a safety boundary, not as a ranking input.
Official context boundary
Read the source behind each category note.
These official context records explain why Peptide Local keeps research listings outside medical and approved-product lanes. They do not certify any seller or material.
FDA lists BPC-157 among bulk substances that may present significant safety risks in compounding and says it lacks sufficient information to know whether it would cause harm when administered to humans.
Read the FDA source ↗FDA identifies thymosin beta-4 fragment (LKKTETQ), often marketed as TB-500, among bulk substances that may present significant safety risks in compounding.
Read the FDA source ↗Continue comparing